Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Health-care companies were more or less flat as traders rotated into higher risk sectors, amid optimism about Iran- and global trade negotiations. Walgreens Boots Alliance shares rose after it ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Illinois has confirmed its first human case of West Nile virus this year, health officials say. The person, who lives in ...

A new study says common human typing errors can trip up artificial intelligence (AI) programs designed to aid health care ...

The Investment Committee discuss their strategy on some stocks on the move today. Mexico President Claudia Sheinbaum tells ...

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) securities ...

(Reuters) -Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug, ...